Evidence map›Paper›PMID 37810186›Full record

ArticleNeuroscience insights2023

Unveiling Resilience to Alzheimer's Disease: Insights From Brain Regional Proteomic Markers.

Zhi Huang, Gennifer E Merrihew, Eric B Larson, Jea Park, Deanna Plubell, Edward J Fox, Kathleen S Montine, C Dirk Keene, Caitlin S Latimer, James Y Zou and 2 more

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Zhi HuangDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Gennifer E MerrihewDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.ORCID https://orcid.org/0000-0003-4903-0318
Eric B LarsonDepartment of Medicine, University of Washington, Seattle, WA, USA.
Jea ParkDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.
Deanna PlubellDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.
Edward J FoxDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Kathleen S MontineDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Caitlin S LatimerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
James Y ZouDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Michael J MacCossDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.
Thomas J MontineDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
University of Washington · USStanford University · US

Funding

Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Paul K Crane, Andrea Z. LaCroix · 2021 to 2026
$80.4M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Project 4: Novel reagent development to enable molecular characterizationU19AG065156 · NIA · UNIVERSITY OF WASHINGTON · PI POSTON, KATHLEEN LOMBARD · 2020 to 2024
$15.9M
Neuropathology of synapses in AD and ADRDRF1AG077443 · NIA · STANFORD UNIVERSITY · PI AGHAEEPOUR, NIMA, MONTINE, THOMAS J · 2023 to 2023
$2.2M
Neuropathology of synapses in AD and ADRDR01AG077443 · NIA · STANFORD UNIVERSITY · PI Nima Aghaeepour, Thomas J Montine · 2026 to 2026
$707k
Proteolytic activity profiling of Alzheimer's dementiaF31AG069420 · NIA · UNIVERSITY OF WASHINGTON · PI PLUBELL, DEANNA LISA · 2020 to 2021
$81k
NIA NIH HHS F31 AG069420NIA NIH HHS P30 AG066509NIA NIH HHS R01 AG077443NIA NIH HHS RF1 AG077443NIA NIH HHS U19 AG065156NIA NIH HHS U19 AG066567
6 · The paper itself

Abstract

Studying proteomics data of the human brain could offer numerous insights into unraveling the signature of resilience to Alzheimer's disease. In our previous study with rigorous cohort selection criteria that excluded 4 common comorbidities, we harnessed multiple brain regions from 43 research participants with 12 of them displaying cognitive resilience to Alzheimer's disease. Based on the previous findings, this work focuses on 6 proteins out of the 33 differentially expressed proteins associated with resilience to Alzheimer's disease. These proteins are used to construct a decision tree classifier, enabling the differentiation of 3 groups: (i) healthy control, (ii) resilience to Alzheimer's disease, and (iii) Alzheimer's disease with dementia. Our analysis unveiled 2 important regional proteomic markers: Aβ peptides in the hippocampus and PA1B3 in the inferior parietal lobule. These findings underscore the potential of using distinct regional proteomic markers as signatures in characterizing the resilience to Alzheimer's disease.

Indexed as

Alzheimer’s diseasedifferential expressionmass spectrometryProteomics

Identifiers

PMID37810186
PMCPMC10557413
OpenAlexW4387368895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.